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Abstract The Wild-type p53-induced phosphatase 1, Wip1
(or PPM1D), is unusual in that it is a serine/threonine
phosphatase with oncogenic activity. A member of the type
2C phosphatases (PP2Cδ), Wip1 has been shown to be
amplified and overexpressed in multiple human cancer
types, including breast and ovarian carcinomas. In rodent
primary fibroblast transformation assays, Wip1 cooperates
with known oncogenes to induce transformed foci. The
recent identification of target proteins that are dephos-
phorylated by Wip1 has provided mechanistic insights into
its oncogenic functions. Wip1 acts as a homeostatic
regulator of the DNA damage response by dephosphorylat-
ing proteins that are substrates of both ATM and ATR,
important DNA damage sensor kinases. Wip1 also sup-
presses the activity of multiple tumor suppressors, includ-
ing p53, ATM, p16
INK4a and ARF. We present evidence that
the suppression of p53, p38 MAP kinase, and ATM/ATR
signaling pathways by Wip1 are important components of
its oncogenicity when it is amplified and overexpressed in
human cancers.
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Abbreviations
ARF alternate reading frame of the ink4a locus
ATM ataxia telangiectasia mutated
ATR ataxia telangiectasia and Rad3-related
BER base excision repair
BRCA1 breast cancer gene 1
Chk1 and 2 checkpoint kinases 1 and 2
DNA-PK DNA-dependent protein kinase
MAPK mitogen-activated protein kinase
MEF mouse embryo fibroblast
Mdm2 mouse double minute 2
MKK6 MAPK kinase 6
MMTV mouse mammary tumour virus
PIKK phosphoinositide-3-kinase-related kinase
PP2C protein phosphatase type 2C
RB retinoblastoma
UNG2 uracil DNA glycosylase 2
Wip1 wild-type p53-induced phosphatase 1
Wnt wingless/INT
1 Introduction
Cellular DNA is constantly exposed to various environ-
mental and endogenous mutagenic insults. To maintain
genomic integrity and prevent cancer in the face of these
potentially mutagenic events, cells have evolved a sophis-
ticated array of damage sensors, signaling molecules, and
repair functions. Among the key sensors of DNA damage are
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that include ATM (ataxia-telangiectasia mutated), ATR
(ataxia-telangiectasia and Rad3-related), and DNA-PKcs
(DNA dependent protein kinase catalytic subunit) [1, 2].
Most PIKKs are serine/threonine kinases that are conserved
from yeast to humans and phosphorylate key target proteins
in various DNA damage response pathways [3, 4]. The
direct importance of the ATM/ATR-initiated damage re-
sponse pathways in cancer prevention has recently been
demonstrated by two groups [5, 6]. Human pre-neoplastic
lesions from a variety of different human cancers were
shown to express markers of an activated DNA damage
response, including activated and phosphorylated ATM,
Chk2, p53, and H2AX [5, 6]. Interestingly, late stage
tumors often showed loss of these DNA damage response
markers, suggesting that the disabling of DNA damage
response pathways is an important prerequisite for cancer
progression [5, 6].
In studies of the DNA damage response, most attention
has been focused on the activation and execution of that
response. Less attention has been given to the reversal of
the response. Once cell division has been halted and the
DNA damage has been repaired, how does the cell return to
its normal pre-stress state and re-enter cell division? Since
activation of the damage response often occurs through
phosphorylation of key downstream targets of ATM/ATR,
phosphatases are obvious candidates as homeostatic regu-
lators of the DNA damage response. In this review we will
discuss the evidence that the Wild-type p53-induced
phosphatase 1, or Wip1, is a major homeostatic regulator
of the ATM/ATR-initiated DNA damage response.
In addition to its homeostatic role in the DNA damage
response, we will also describe how Wip1 downregulates
importanttumor suppressor molecules.Wip1hasbeenshown
to inhibit p53 by multiple mechanisms and to downregulate
p38 MAP kinase through dephosphorylation [5, 7–11].
Expression of p16
INK4a and p14
ARF have also been shown
to be suppressed in some contexts by Wip1 [12]. The
inhibition of these tumor suppressors is likely to be a major
component of the oncogenic activity of this phosphatase.
2 Discovery and initial characterization of Wip1
Appella and colleagues originally identified the human
Wip1 gene by screening for genes induced in a p53-
dependent manner in response to ionizing radiation (IR) in
WMN Burkitt lymphoma cells [13]. Using mRNA differ-
ential display methodology, they identified a novel p53-
induced gene. The Wip1 transcript was induced by
ultraviolet (UV) and IR in a p53-dependent manner [13].
Tumor cell lines with wild-type p53 consistently showed
IR-induced increases in Wip1 mRNA while p53-deficient
cell lines showed little or no induction of Wip1 expression
following radiation treatment. Cellular fractionation and
indirect immunofluorescence indicated that the 61 kDa
Wip1 protein localizes to the nucleus [13].
The 605 amino acid human Wip1 protein sequence can
be subdivided into two major domains, a highly conserved
N-terminal phosphatase domain from amino acids 1–375,
and a less conserved non-catalytic domain extending from
amino acids 376–605. This C-terminal domain of Wip1
may facilitate nuclear localization. However, although this
domain contains two putative nuclear localization signals,
mutation of these motifs failed to prevent nuclear localiza-
tion [14]. In addition, the C-terminal domain shows high
conservation among mammalian Wip1s and limited con-
servation with non-mammalian Wip1 molecules, but little
or no similarity with other phosphatases (Fig. 1). The
phosphatase domain of Wip1 shows the highest levels of
similarity to the type 2C family of serine/threonine protein
phosphatases (PP2C), consistent with its observed bio-
chemical activities (Fig. 1(b)) [13, 15].
Using the human Wip1 cDNA as a probe, our laboratory
isolated the murine Wip1 gene and mapped it to mouse
chromosome 11 [16]. The human Wip1 gene is located on
chromosome 17q22/q23 [17]. The murine Wip1 protein
contains 598 amino acids and migrates at approximately
66 kDa on a SDS-PAGE gel [16]. The murine and human
Wip1 protein sequences have an overall identity of 83%
and an overall similarity of 86%. RT-PCR and Northern
blot analyses revealed that the Wip1 mRNA is ubiquitously
expressed in all mouse embryonic and adult tissues, with a
very high level of expression in the testis. Wip1 mRNA
levels fluctuate during development [16].
3 Wip1 is a type 2C phosphatase
Wip1 is a member of the magnesium-dependent serine/
threonine protein phosphatase (PPM) family [18, 19]. This
is a large and varied family of protein phosphatases present
in both prokaryotes and eukaryotes, whose defining
member is PP2Cα [20, 21]. To date, 18 human PPM/
PP2C genes have been identified [19]. In prokaryotes and
eukaryotes, the PPM/PP2C family of phosphatases plays a
role in regulating stress response pathways [18, 20, 21].
Like other PPM/PP2C family members, Wip1 is a
monomeric enzyme that requires divalent cations, mainly
Mg
2+ or Mn
2+, for catalytic efficacy and is insensitive to
okadaic acid, a potent inhibitor of the PP1 and PP2A
phosphatases [18, 20, 21]. Using a BLAST search of the
sequence database, human Wip1 shows an overall identity
of 30% and an overall similarity of 45% to human PP2Cα
and PP2Cβ (Fig. 1(b)). Like PP2Cα and PP2Cβ, Wip1 also
negatively regulates the stress responsive p38 mitogen-
124 Cancer Metastasis Rev (2008) 27:123–135activated protein kinase (MAPK) pathway by directly
inactivating p38 through dephosphorylation of phospho-
threonine 180 of the regulatory pTXpY motif found in the
activation loop of the kinase [11, 22, 23].
Based on the sequence homology between Wip1 and
PP2Cα, β, and γ, Yamaguchi et al. [15] developed a
structural model for the catalytic domain of Wip1. From
these studies, Arg76 of human Wip1 (Arg69 of mouse
Wip1) aligned with Arg33 of PP2Cα, suggesting that
Arg76 of human Wip1 performs the same role as the
catalytic Arg33 of PP2Cα. Substrate specificity studies
indicated that peptides containing pSXpY inhibit Wip1,
while pTXpY peptides are Wip1 substrates [24]. Sequences
on either side of the pTXpY motif did not greatly affect
Wip1 activity, but the residue (X) lying between the two
conserved phospho-acceptors affected Wip1 affinity and
correlated with selectivity for MAP kinases. From these
studies a specific Wip1 inhibitor was developed, and using
simulations with the proposed structural model of Wip1, the
phospho-Ser of the inhibitor was shown to be in contact
with the proposed catalytic Arg76, thus blocking its
interaction with potential targets [24].
While the specificity of Wip1 for pTXpY motifs is clear
from biochemical and cell biology studies [11, 15, 24, 25],
the recent identification of targets in which Wip1 dephos-
phorylates sites modified by ATM/ATR indicates an
additional specificity. ATM and ATR phosphorylate pS/
pTQ sites in over 700 proteins in the cell [4] and Wip1 has
been shown to dephosphorylate pS/pTQ sites in vitro and in
vivo on at least five proteins, ATM, Chk1, Chk2, p53, and
Mdm2 (see Fig. 2)[ 7–9, 26].
4 Identification of Wip1 targets reveals
it to be a homeostatic regulator of the DNA damage
response
4.1 Wip1 dephosphorylates DNA damage response/repair
proteins at TXY motifs
Once Wip1 was shown to be a serine/threonine phospha-
tase, it was clear that its functional roles might best be
understood by identifying Wip1 target proteins and dephos-
phorylation sites. Since the discovery of Wip1, at least
seven Wip1 dephosphorylation targets have been defini-
tively identified. These are listed in Table 1. Note that on
the seven target proteins, two distinct motifs appear to be
dephosphorylated by Wip1, pTXpY and pS/pTQ. One key
commonality is their importance in the cellular DNA
damage/repair response. Wip1 acts as an inhibitor or
Fig. 1 Protein sequence alignment of human Wip1 and human
PP2Cα.( a) The overall structures of Wip1 (top) and PP2Cα (bottom)
show significant similarity. The conserved type 2C phosphatase
domain is shaded in Wip1. The regions of more highly conserved
sequences labeled I, II, and III are shown as black blocks. The C-
terminal non-catalytic domain that is present only in Wip1 molecules
(and is also well conserved among mammalian Wip1 orthologues) is
indicated by the white block. A putative nuclear localization signal
(NLS) isalsoindicated neartheC-terminusofWip1.(b) Primary amino
acid sequence alignment between human Wip1 and human PP2Cα
phosphatase domains is shown. Identical amino acids are highlighted
with a black background while conservative amino acid substitutions
are indicated with a gray background. The phosphatase domains of the
two molecules show 30% identity and 45% similarity
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tating the return of the cell to a normal pre-stress state
followingrepairoftheDNAdamage.AsindicatedinTable 1,
five of the seven identified dephosphorylation targets are
phosphorylated by the PIKKs ATM and ATR, which are key
sensor proteins that activate numerous components of the
DNA damage response pathways in the cell. We hypothe-
size that Wip1 serves as a major off switch for the ATM/
ATR-initiated DNA damage signaling cascade [7, 26]. Note
also that six of the seven Wip1 targets are important
regulators of p53 function. The four kinases p38, Chk1,
Chk2, and ATM all phosphorylate p53 and promote its
Table 1 Identified Wip1 dephosphorylation targets
Protein Site
a Motif Kinase Protein function Wip1 effects p53 effect? Reference
p38 MAPK T180 TXY MKK3/6 Stress response Dec. kinase activity Yes (dec.) Takekawa et al. [11]
UNG2 T6 TXY ? Base excision repair Dec. uracil excision No Lu et al. [25]
Chk1 S345 S/TQ ATR DNA damage response Dec. kinase activity Yes (dec.) Lu et al. [10]
p53 S15 S/TQ ATM DNA damage response Dec. apoptosis Yes (dec.) Lu et al. [10]
Chk2 T68
b S/T/Q ATM DNA damage response Dec. kinase activity Yes (dec.) Fujimoto et al. [9]
ATM S1981 S/TQ ATM
c DNA damage response Dec. kinase activity Yes (dec.) Shreeram et al. [7]
Mdm2 S395 S/TQ ATM p53 regulation Dec. p53 levels Yes (dec.) Lu et al. [8]
aListed sites are from the human proteins; mouse sites (e.g. p53 S18 or ATM S1987) may be at different amino acid codons
bAlso sites Ser19, Ser33/35, Thr68, and Thr432
cActivated ATM autophosphorylates itself at S1981; S367 also dephosphorylated by Wip1
Fig. 2 Wip1 inhibits p53 activity by multiple mechanisms. When a
cell is stressed by DNA damage, ATM, ATR, and p38 MAP kinase
can phosphorylate p53 directly or through intermediary proteins such
as Chk1 and Chk2. Phosphorylated p53 localizes to the nucleus and
transactivates a battery of anti-proliferative genes. In addition, two p53
autoregulatory genes are activated, Mdm2 and Wip1. Mdm2 is an E3
ubiquitin ligase that promotes p53 degradation. However, early after
the DNA damage response ATM (and possibly ATR) phosphorylate
Mdm2 and this promotes Mdm2 degradation and prevents Mdm2
mediated p53 degradation. Activated p53 also upregulates Wip1
expression and after DNA damage is repaired, the accumulated
Wip1 phosphatase inhibits a battery of proteins that activate p53. Wip1
dephosphorylates the upstream kinases that phosphorylate p53 (ATM,
p38, Chk1, Chk2) and p53 itself (at Ser15). In addition, Wip1
dephosphorylates Mdm2 at Ser395 and this results in Mdm2
stabilization and Mdm2 mediated p53 degradation. Finally, increased
Wip1 levels suppresses ARF which in turn results in increased Mdm2
activity and p53 proteolysis. The resulting destabilization of p53 helps
return the normal cell to a pre-stress state after cellular damage is
repaired. However, if Wip1 becomes amplified or overexpressed
during tumor cell progression, this could result in chronic suppression
of p53 activity and promote tumorigenesis. In the figure, proteins are
indicated by circles or octagons and genes are indicated by rectangles.
Small circles marked with P indicate phosphorylation sites. Black lines
indicate early events in the DNA damage response and gray lines
show later homeostatic events in the damage response
126 Cancer Metastasis Rev (2008) 27:123–135activation [27–30]. Wip1 dephosphorylation of these p53
kinases decreases their intrinsic activity. Dephosphorylation
of p53 at serine 15 by Wip1 also contributes to p53
degradation, as does dephosphorylation of Mdm2, which
stabilizes Mdm2, an E3 ubiquitin ligase specific for p53
[31]. Thus, Wip1 appears to be a critical inhibitor of p53
function and such effects are likely to play a major role in
Wip1 oncogenicity (see below). In this section, we will
describe the proteins, which have been identified as targets
for dephosphorylation by Wip1 and how Wip1 regulates the
function(s) of these proteins.
4.1.1 TXY motif: p38
The first identified target of Wip1 was the p38 mitogen-
activated protein kinase (p38 MAP kinase) [11]. Genotoxic
stress such as UV radiation causes activation of p38 MAP
kinase by dual phosphorylation on Thr180 and Tyr182 [32,
33]. The phosphorylated p38, in turn, phosphorylates p53
on Ser15, Ser33, Ser46 and Ser392 and increases p53
activities, including gene transcription and apoptosis [28,
34, 35]. p38 was shown to interact with Wip1 and to be
dephosphorylated by Wip1 on its Thr180 residue [11].
Wip1 dephosphorylation of p38 was associated with
reduced nuclear localization of p38 and reduced kinase
activity towards Ser33 and Ser46 of p53 [11]. Dephosphor-
ylation of Ser33 and Ser46 on p53 was accompanied by
reduced p53 transcriptional activation activity and reduced
p53-mediated apoptotic function following UV irradiation.
Thus, Wip1 inhibits UV-induced phosphorylation of p53 on
Ser33 and Ser46 via p38 downregulation, functioning as a
mediator in a p53 negative feedback regulatory loop.
4.1.2 TXY motif: UNG2
Uracil is a common DNA lesion formed by deamination of
cytosine or misincorporation of dUMP, leading to transition
mutations or generation of AP sites (apurinic/apyrimidinic
sites) in the genome. Such lesions are repaired by base
excision repair (BER) that is initiated by a uracil DNA
glycosylase [36]. At least four different mammalian uracil
DNA glycosylases have been identified. Of these, the
nuclear UNG2 encoded by the UNG gene is the major
enzyme responsible for removing uracil and creating an
apyrimidinic site for further repair processing [36].
To identify Wip1 interacting proteins, our laboratory
performed bacterial two-hybrid assays with Wip1 bait
constructs and we repeatedly pulled down UNG2 as a
major interactor. In vitro and in vivo interaction studies by
us and global human interactome screens by others
confirmed that UNG2 is a Wip1 interacting protein [25,
37]. Analysis of the UNG2 sequence revealed two TXY
motifs at Thr6 and Thr126, which show similarities to the
Wip1 target site on p38 MAP kinase. We utilized UNG2
phosphothreonine 6 and 126 specific antibodies generated
by the Appella laboratory to show that UV irradiation
induced UNG2 phosphorylation at both Thr residues and
that this enhances UNG2 enzymatic activity. Of these two
target residues, only Thr6 was dephosphorylated by Wip1
in cells. Dephosphorylation of UNG2 by Wip1 resulted in
reduced uracil-associated DNA incision activity, a critical
step in BER [25]. Moreover, we were able to show that
human cell lines overexpressing a Wip1 expression con-
struct exhibited reduced global BER activity, while the
same cells transfected with Wip1 siRNA exhibited
enhanced global BER activity, indicating Wip1 inhibits
base excision repair, in part by dephosphorylating UNG2
[25, 38].
4.2 Wip1 dephosphorylates DNA damage response proteins
at S/TQ motifs
4.2.1 S/TQ motif: Chk1, Chk2
The checkpoint kinases Chk1 and Chk2 are evolutionarily
conserved kinases which play a crucial role in regulating
DNA damage responses [39]. In response to DNA damage
or replicative stress, Chk1 is phosphorylated on Ser317 and
Ser345 mainly by the ATR kinase [40]. The phosphoryla-
tion on these two serine residues is a critical event for Chk1
activation in that mutants of Chk1 in which Ser317 and
Ser345 residues were replaced with alanine showed poor
kinase activity. Following activation, Chk1 phosphorylates
and inactivates Cdc25 phosphatase family members to
facilitate cell cycle arrest [41].
Chk2 activation is a multistep process initiated by
phosphorylation on Thr68 mainly by ATM in response to
DNA damage [42, 43]. Although Thr68 phosphorylation is
not the only requirement for full activation of Chk2, the
T68A mutation significantly reduced Chk2 kinase activity
[44]. Activated Chk2 targets a variety of proteins involved
in cell cycle control, DNA repair and apoptosis, including
p53, BRCA1, PML, E2F-1, and the Cdc25 phosphatase
family. Notably, ATR-Chk1 and ATM-Chk2 pathways are
not strictly separated but rather highly connected and
coordinated as evidenced by ATM-dependent phosphoryla-
tion of Chk1 in response to ionizing radiation [45], ATM-
independent activation of Chk2 [46], and ATR activation
regulated by ATM [47, 48].
The identification of Chk1 as a Wip1 target followed co-
immunoprecipitation experiments in our laboratory that
showed that Wip1 consistently bound Chk1 in cells [10]. In
vitro phosphatase assays showed that Wip1 dephosphory-
lated Chk1 at Ser345, but not Ser317. In vivo assays
demonstrated that overexpressed Wip1 suppressed UV-
induced phosphorylation of Chk1 Ser345 while Wip1
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controls. Importantly, dephosphorylation of Chk1 at Ser345
resulted in reduced Chk1 kinase ability on Chk1 targets such
as Cdc25C. Since Chk1 is an important cell cycle checkpoint
protein, we also assessed the effects of either increasing or
decreasing Wip1 expression on G2/M and intra-S phase
checkpoints. As expected, increased levels of Wip1 abrogat-
ed G2/M and intra-S phase checkpoints, while decreased
levels of Wip1 enhanced G2/M and intra-S phase check-
points induced by both UV and IR treatment of cells [10].
Because Chk1 phosphorylates and activates p53, the
inhibition of Chk1 by Wip1 also places Wip1 in a negative
feedback regulatory loop for p53 (Fig. 2)[ 26].
Chk2 was also shown to directly interact with Wip1 in
vitro and in vivo by Fujimoto et al. [9]. These investigators
showed that Thr68, which is phosphorylated by ATM after
IR treatment, is dephosphorylated efficiently by Wip1.
Moreover, Wip1 also dephosphorylated several other S/TQ
sites within Chk2. Overexpression of Wip1 was shown to
suppress Chk2 kinase activity towards its substrate
Cdc25C, while inhibition of Wip1 resulted in both
increased and prolonged Chk2 kinase activity following
IR. Interestingly, treatment of gamma-irradiated cells with
Wip1 siRNA enhanced IR-induced apoptosis, suggesting
that Wip1 negatively regulates irradiation-induced apopto-
sis by dephosphorylating and inactivating Chk2. Several
laboratories have corroborated the inhibition of Chk2
activity by Wip1 and have shown that cancer cells with
amplified Wip1 show reduced Chk2 activity [14, 49–51].
4.2.2 S/TQ motif: p53
The tumor suppressor p53 is a central node in the DNA
damage response and mediates an array of responses,
including the activation of multiple cell cycle checkpoints,
DNA repair and apoptosis [52]. The importance of p53 in
cancer prevention is supported by the observation that
about half of all human cancer patients harbor p53
mutations [53]. Moreover, p53 deficient mice are highly
susceptible to early onset spontaneous tumors [54]. In
unstressed cells, p53 is maintained at low levels as a result
of Mdm2-mediated ubiquitination and degradation [55].
When cells are confronted by genotoxic stress, ATM, ATR
and Chk1/2 kinases phosphorylate p53. This phosphoryla-
tion, along with modifications of other residues, blocks the
p53-Mdm2 interaction, leading to p53 stabilization and an
increase in p53 activity [56].
We investigated whether Wip1 dephosphorylated p53 at
Ser15. In fact, both p53 phosphopeptides containing
phosphoserine 15 and intact immunopurified p53 were
efficiently dephosphorylated at Ser15 by purified Wip1 in
vitro [10]. UV-irradiated cells exhibited reduced p53 Ser15
phosphorylation in the presence of overexpressed Wip1 and
greatly augmented and sustained p53 Ser15 phosphoryla-
tion in the presence of Wip1 siRNA. As expected, increased
Ser15 phosphorylation correlated with increased p53
protein levels in irradiated Wip1 siRNA treated cells.
4.2.3 S/TQ motif: Mdm2
The decreased stability of p53 in the presence of high Wip1
levels led us to investigate whether or not the effects of
Wip1 on p53 stability are mediated by Mdm2. Mdm2 is an
E3 ubiquitin ligase that specifically targets p53 for
destruction [55]. Mdm2 binds to p53 and mediates its
polyubiquitination as a prelude to its transport to the 26S
proteosome and proteolytic degradation. Importantly, DNA
damage results in ATM phosphorylation of Mdm2 at
Ser395 and this phosphorylation is associated with Mdm2
destabilization [31]. Phosphorylation at this site also inhibits
Mdm2 interactions with p53. Thus, p53 is stabilized.
We had noted that reduction of Wip1 levels corre-
sponded with increased sustained p53 protein levels and
increased p53 transcriptional activity after IR-induced DNA
damage [8, 49]. One explanation for these observations was
that Wip1 was affecting p53 stability through effects on
Mdm2. To assess this possibility, we examined Wip1
interactions with Mdm2 and found that endogenous Wip1
and endogenous Mdm2 could form protein-protein inter-
actions [8]. Moreover, Wip1 was shown to dephosphorylate
Mdm2 at Ser395 both in vitro and in vivo. Dephosphory-
lation of Mdm2 by Wip1 was associated with decreased
Mdm2 self-polyubiquitination and increased Mdm2 stabil-
ity. Prevention of Mdm2 Ser395 dephosphorylation by
Wip1 siRNA treatment destabilized Mdm2 following
irradiation [8]. As expected, Wip1 overexpression increased
Mdm2 interaction with p53 and increased p53 polyubiqui-
tination, facilitating p53 proteolytic degradation. Thus, a
primary role of Wip1 is to inhibit p53 stability in part
through augmenting Mdm2 stability as a consequence of
Mdm2 Ser395 dephosphorylation (Fig. 2).
4.2.4 S/TQ motif: ATM
ATM is a sensor kinase that is rapidly activated by DNA
double strand breaks in part through autophosphorylation at
Ser1981 (or Ser1987 in the mouse). Activated ATM then
phosphorylates a diverse array of effector molecules that
induce cell cycle arrest, DNA repair, DNA replication, and
apoptosis. Activated ATM phosphorylates its targets at S/
TQ sites and it has recently been shown by Elledge and
colleagues in a global proteomic screen that ATM/ATR
phosphorylates over 700 protein targets with widely
different functions [4].
Bulavin and colleagues have demonstrated that Wip1
null mouse embryo fibroblasts (MEFs) treated with IR
128 Cancer Metastasis Rev (2008) 27:123–135exhibit higher levels of Ser1987 phosphorylation, indicat-
ing higher levels of ATM activity [7]. Wip1 was shown to
directly interact with ATM and its overexpression resulted
in decreased levels of Ser1981 phosphorylation following IR
treatment. Conversely, downregulation of Wip1 using
siRNA resulted in increased Ser1981 phosphorylation.
Moreover, immunopurified ATM was efficiently dephos-
phorylated at Ser1987 by purified Wip1, as was a phospho-
peptide derived from this part of ATM. More recently,
Shreeram et al. [57] have also shown that Wip1 dephos-
phorylates human ATM at Ser367 as well as Ser1981. The
authors concluded that Wip1 was important in resetting
ATM phosphorylation after repair of DNA damage.
5 Wip1 is an oncogene
While a significant number of tyrosine phosphatases are
associated with cancer initiation or development [58], few
serine/threonine phosphatases have been directly associated
with oncogenesis. The only well characterized serine/
threonine phosphatase involved in oncogenic signaling is
the phosphatase PP2A. PP2A has tumor suppressor activity
and its inactivation has been associated with transformation
of human primary cells [59]. It has also been shown to be
either mutated or downregulated in some human cancers.
Among the type 2C phosphatases, Wip1 appears to be the
only one described so far with bona fide oncogenic
function. The regulatory functions of Wip1 in the ATM-
CHK1/2-p53 and p38 MAPK-ARF/p16
INK4A signaling
pathways would argue that this protein may possess major
oncogenic potential.
The first evidence of an oncogenic role for Wip1 was
published in a pair of papers by Bulavin et al. [17] and Li et
al. [60]. Bulavin et al. used tissue microarray profiling to
show that 37 of 326 primary breast tumors (11.3%) had
Wip1 gene amplification. Similarly, Li et al., using DNA
microarray analysis, showed that Wip1 was amplified at
least 2.5 fold in 27 of 164 (16%) primary breast cancers.
Both laboratories demonstrated that overexpression of Wip1
mRNA correlated well with Wip1 gene amplification.
Interestingly, only one of eight tumors with Wip1 amplifi-
cation examined by Bulavin et al. had a p53 mutation. The
infrequent nature of p53 mutations in tumors with Wip1
amplification suggests that Wip1 may promote human
tumors through its ability to inhibit p53, circumventing
selective pressure to mutate p53 during tumor progression.
Wip1 amplification in this context is reminiscent of tumors
with Mdm2 amplification, where Mdm2 promotes degrada-
tion of p53 and few of these tumors exhibit p53 mutations
[61]. Since these initial reports, other groups have con-
firmed amplification and overexpression of the Wip1 gene
in breast cancers [62, 63]. Rauta et al. [62] showed Wip1
gene was amplified in 11% of breast cancers and this
amplification was highly associated with ErbB2 amplifica-
tion. Moreover, these investigators observed that breast
cancers with Wip1 amplification had a significantly poorer
prognosis than those without Wip1 amplification, though a
breast cancer study by Yu et al. [63] failed to detect an
effect of Wip1 overexpression on prognosis. In addition to
breast cancers, Wip1 amplification and overexpression have
been observed in ovarian clear cell adenocarcinomas [64],
neuroblastomas [65], pancreatic adenocarcinomas [66],
gastric carcinomas [51], and medulloblastomas [67–69]
(Table 2). As shown in Table 2, where it was examined,
tumors with Wip1 amplification rarely contained p53 muta-
tions and often exhibited poorer prognosis than their counter-
parts with normal Wip1. Since only a handful of tumor types
have been reported, it remains to be seen whether Wip1
amplification and overexpression occurs in most tumor types
Table 2 Human tumors with Wip1 gene amplification and/or overexpression
Organ/Type DNA/RNA increase p53 mutation Prognosis
a Reference
Breast adenocarcinoma (11% CNG
b; ECG
c) 1/8 Bulavin et al. [17]
(16% CNG; ECG) Li et al. [62]
(11% CNG; ECG) 1/10 Poorer Rauta et al. [64]
(35% O
d) Yu et al. [65]
Ovarian clear cell adenocarcinoma (40% CNG; ECG) Poorer Hirasawa et al. [66]
Neuroblastoma (92% CNG; 28% O) 2/32 Poorer Saito-Ohara et al. [67]
Medulloblastoma (51% CNG; 88% O) Poorer Mendrzyk et al. [70]
(37% CNG; 27% O) Ehrbrecht et al. [69]
Gastric carcinoma (74% O) Fuku et al. [53]
Pancreatic adenocarcinoma (36% CNG) Poorer Loukopoulos et al. [68]
aPrognosis: “Poorer” indicates individuals with tumors with increased Wip1 copy number and/or expression have significantly poorer prognosis
than all individuals with that type of tumor
bCNG: Wip1 DNA copy number gain (compared to DNA in normal tissues)
cECG: increased Wip1 RNA expression significantly correlates with copy number gain
dO: percentage of tumors with Wip1 RNA overexpression
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p53 mutations might circumvent p53 mutation or loss by
Wip1 functional inactivation of p53 and these tumors would
be good candidates for further investigation.
In their papers describing the initial discovery of Wip1
amplification and overexpression in breast cancers, Bulavin
et al. [17] and Li et al. [60] were also able to show that
Wip1 can collaborate with known oncogenes such as Ras,
Myc and Neu to transform rodent wild type primary
fibroblasts and induce anchorage-independent growth in
soft agar. It was also shown by both groups that over-
expression of Wip1 could abrogate Ras-induced senescence
of primary cells and could prevent apoptosis induced by
serum starvation. Interestingly, transformation assays on
p53 null MEFs showed that while Ras, Neu and Myc
oncogenes could individually transform these cells, Wip1
could not [17]. These results argued that Wip1 is primarily
oncogenic as a result of its ability to inhibit p53 signaling.
In later studies, our laboratory was able to show that Wip1
transformation of primary rat embryo fibroblasts, in
conjunction with the adenoviral E1A oncogene, was
dependent on the phosphatase activity of Wip1 [49]. In
contrast to wild-type Wip1, the phosphatase-dead mutant
Wip1 (D307A) failed to transform primary fibroblasts.
To further demonstrate that Wip1 is oncogenic in an in
vivo context, Demidov et al. [70] overexpressed Wip1 as a
transgene in the mouse mammary gland. While the Wip1
transgenic mice did not develop spontaneous mammary
tumors, the appearance of mammary tumors was accelerat-
ed when these animals were crossed with mammary tumor
susceptible ErbB2 transgenic mice. Interestingly, the tumor
promoting effects of the Wip1 transgene in the ErbB2
transgenics could be lost by further crossing in a constitu-
tively activated MKK6 transgene [70]. MKK6 activates p38
MAP kinase and thus nullifies the effects of Wip1
dephosphorylation of p38, demonstrating the importance
of Wip1 in regulating p38 signaling as well as p53
signaling in this particular model.
6 Mechanisms of Wip1 oncogenicity
Wip1 overexpression in MEFs and in transgenic mice
promotes cell transformation and accelerated cancer pro-
gression [17, 49, 60, 70]. Moreover, a number of human
cancers contain amplified and overexpressed Wip1 (Table 2).
Generally, these tumors do not contain p53 mutations,
suggesting that overexpressed Wip1 inhibits p53 during
tumor progression, consistent with the fact that Wip1
suppresses p53 activity in the normal cellular context
(Fig. 2). As an alternative approach to assess Wip1 function
in promoting tumorigenesis, Wip1-deficient mice were
generated in our laboratory. Wip1 null mice are viable but
show some postnatal abnormalities, including variable male
runting, male reproductive organ atrophy, reduced male
fertility, and reduced male longevity [71]. The Wip1 null
mice also showed increased susceptibility to pathogens and
diminished T- and B-cell function.
Fibroblasts derived from Wip1 null embryos showed
reduced growth rates, reduced colony forming ability, and
premature senescence compared to their wild-type counter-
parts [12, 71]. In addition, Wip1 null MEFs exhibited an
enhanced G1 checkpoint response to ionizing radiation.
Bulavin et al. [12] showed that Wip1 null fibroblasts were
significantly more resistant to transformation by various
combinations of oncogenes compared to wild-type MEFs.
Hras1 plus the adenoviral E1A oncogene transformed
Wip1−/− MEFs displayed increased expression of p53 and
cyclin dependent kinase inhibitors p21, p16
INK4A,a n d
p19
ARF compared to Wip1+/+ MEFs. In addition, the p38
MAP kinase showed increased phosphorylation in Wip1−/−
MEFs [12]. Increases in p53, p21, and phosphorylated p38
MAP kinase in Wip1 null MEFs are supported by the fact
that Wip1 directly dephosphorylates p38 and p53 and
regulators of p53 (ATM, Chk1, Chk2). Since p21 is
transcriptionally upregulated by p53, the increase in its
levels is attributable to p53 activation.
One interesting result in these transformed Wip1 null
MEF studies was the increase in p19
ARF and p16
INK4a
levels. Wip1 regulation of these cyclin dependent kinase
inhibitors appears to be at the transcriptional level, as
transformed Wip1 null MEFs showed a three- to fourfold
enhancement of transfected p16 promoter driven luciferase
expression and p19 promoter driven CAT expression when
compared to wild-type MEFs. Bulavin et al. [12] further
showed that oncogene transformed p53 null MEFs produce
tumors when transplanted into nude mice, while trans-
formed doubly null p53 and Wip1 MEFs were resistant to
tumors. Thus, Wip1 must regulate other pathways in
addition to p53 to promote tumorigenesis, at least in this
MEF model system. In contrast to p53−/− Wip1−/− MEFs,
MEFs from Cdkn2a−/− (null for both p16 and p19,
encoded from the same locus) Wip1−/− mice readily formed
nude mouse tumors after oncogene transformation. This
indicated that p16 or p19 or both genes were responsible for
the Wip1 null MEF resistance to tumors. Subsequent
experiments showed that much (though not all) of the
transformation resistance was provided by p19
ARF [12].
Bulavin et al. [12] also tested the effects of Wip1
deficiency on tumorigenesis in an in vivo context. Three
mammary tumor susceptible models, MMTV promoter
driven ErbB2, Hras1, and Wnt1 transgenic mice were
crossed to Wip1 deficient mice and oncogene driven
mammary tumorigenesis was examined in the presence
and absence of Wip1. Wip1 female null mice were
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presence of the MMTV-HRas1 and MMTV-ErbB2 trans-
genes than were their Wip1 wild-type counterparts. How-
ever, Wip1 female null mice with the MMTV-Wnt1
transgene developed mammary cancers at the same rate as
transgenic Wip1 wild-type females. Interestingly, the Wip1
null MMTV-ErbB2 tumors displayed a reduced mitotic
index and an increased apoptotic cell index compared to the
Wip1 wild-type MMTV-ErbB2 tumors. Moreover, p16
INK4a
protein levels in the Wip1 null tumors were low or absent,
suggesting that loss or inactivation of high p16 expression
(probably by p16 promoter methylation) is a likely
prerequisite for tumor progression in this model. It was
also observed that these Wip1 null mammary tumors also
contained high levels of activated p38 MAP kinase (as
indicated by increased levels of phosphorylated p38).
Inhibition of p38 in the MMTV-ErbB2 Wip1 null mice by
repeated injection of the inhibitor SB203580 resulted in the
accelerated development of mammary tumors compared to
water injected mice of the same genotype. Thus, constitu-
tive activation of p38 MAP kinase in the absence of Wip1
may contribute to tumor resistance in the Wip1−/− MMTV-
ErbB2 mice.
In another transgenic mouse model Shreeram et al. [57]
examined lymphoma incidence in Wip1+/+, Wip1+/− and
Wip1−/− mice bearing the Eμ-myc transgene in which Myc
overexpression is restricted to B lymphocytes. Wip1+/− and
Wip1−/− mice exhibited a significant delay in Eμ-Myc-
induced B cell lymphoma incidence. The median lifespan
of Wip1+/+ Eμ-Myc mice was 77 days compared to
107 days for Wip1+/− Eμ-Myc mice and 138 days for
Wip1−/− Eμ-Myc mice [14]. Subsequent crosses of the
Wip1-deficient Eμ-Myc transgenic mice to p53, p19
ARF,
and ATM-deficient mice showed that Wip1 deficiency
suppressed Eμ-Myc-induced lymphomagenesis in an ATM
and p53-dependent, but ARF-independent manner [57].
Thus, overexpression of Wip1 in an oncogenic context
could contribute to tumor promotion by inhibiting both p53
and ATM functions.
In addition to delaying oncogene-induced tumors, we
found that Wip1 absence also resulted in far fewer
spontaneous cancers than in mice with normal levels of
Wip1 [49]. Lifelong monitoring of Wip1+/+ mice recorded
a 45% incidence of spontaneous cancers, while Wip1+/−
and Wip1−/− mice had a cancer incidence of 25% and 10%,
respectively. These differences in tumor incidence between
the Wip1+/+ and Wip1−/− mice were significant (P=0.016).
These results suggest that the absence of Wip1 confers a
significant degree of resistance to cancer development over
the lifespan of the mouse.
Part of the cancer resistance phenotypes of the Wip1 null
mice may have been due to an enhanced DNA damage
response in Wip1−/− tissues. Following whole body
irradiation with 5 Gy, Wip1−/− tissues often exhibited
increased phosphorylation of the DNA damage response
proteins p53 (Ser15), Chk1 (Ser345), Chk2 (Thr68), and
p38 (Thr180) compared to similar Wip1+/+ tissues [49].
These results suggested that an enhanced DNA damage
response might be one mechanism for the cancer resistance
of Wip1 null mice, consistent with recent findings that the
DNA damage response may be an important early failsafe
system in preventing cancer progression [5, 6].
In summary, the studies described in this section and the
previous section provide compelling evidence that Wip1 is a
human oncogene. Table 3 recapitulates some of the evidence
provided above in support of Wip1 oncogenic function. Its
amplification and overexpression in human tumors, its clear
effects on transformation of cells in culture and effects on
tumorigenesis in animal models, and its ability to inhibit the
activity of multiple tumor suppressors clearly define it as an
oncogene. Perhaps the most important tumor suppressor
modulated by Wip1 is the p53 protein. As shown in Fig. 2,
Wip1 inhibits upstream kinase activators of p53 (ATM, p38,
Chk1, Chk2), dephosphorylates p53 itself at Ser15, stabilizes
a key mediator of p53 degradation, Mdm2, and inhibits the
ARF upstream activator of p53. Its inhibition of p16
INK4a
levels also suggests Wip1 activity in suppressing retinoblas-
toma (Rb) tumor suppressor regulated pathways.
Table 3 Evidence that the Wip1 gene is an oncogene
Evidence References
1. Wip1 specifically inhibits p53 signaling by multiple mechanisms [8–12, 17]
2. Wip1 inhibits the activity of other tumor suppressors (ARF, p16
INK4A)[ 12]
3. Wip1 abrogates DNA damage response pathways and cell cycle checkpoints [10, 25, 51]
4. Wip1 can transform primary rodent fibroblasts in conjunction with other oncogenes [17, 51, 62]
5. Wip1 accelerates tumorigenesis in a mammary tumor susceptible model [72]
6. Wip1 is amplified and overexpressed in multiple types of human tumors [17, 62, 64–71]
7. Wip1 amplification and overexpression is often associated with poorer prognosis [64, 66, 67, 68, 70]
8. Wip1 null primary embryo fibroblasts are resistant to transformation by oncogenes [12]
9. Wip1 null mice are resistant to spontaneous and oncogene-induced tumors [12, 51, 59]
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Because Wip1 inhibits so many tumor suppressor mole-
cules (p53, ATM, p16
INK4A, p14/p19
ARF), targeting Wip1
function in cancer cells may be an effective way to enhance
tumor suppressor function, resulting in enhanced cancer
cell arrest and/or apoptosis. A number of laboratories have
begun to experiment with this approach by developing and
characterizing inhibitors of Wip1 phosphatase activity.
Yamaguchi et al. [24] have developed a series of substituted
linear and circular phosphopeptides that variably inhibited
Wip1 activity. Optimization experiments resulted in two
thioether cyclic phosphopeptides with a pSIpY core motif
with essentially 100% inhibition of recombinant Wip1
phosphatase activity. Molecular modeling experiments
indicated close interaction of the cyclic inhibitor with the
key postulated catalytic residues (R76 and K238) in Wip1.
Moreover, the inhibitor was specific for Wip1 and did not
inhibit PP2A or PP2Cα [24].
Another approach was taken by Bulavin and colleagues
who screened a diversity set library of 1990 compounds
and identified 14 that could completely inhibit Wip1
phosphatase activity [72]. Two of these compounds were
highly effective at concentrations as low as 0.5 μM and
most of these hits did not inhibit PP2Cα and PP2A. When
transformed MEFs were incubated with each of the 14
Wip1 inhibitors and tested for p38 MAPK phosphorylation
(the prototype Wip1 target), only 5 of the compounds
increased phosphorylation of p38. The most effective of
these (compound M) was tested on various breast cancer
cell lines and found to reduce cell viability by 30–50% in
some lines and could also potentiate the anti-proliferative
effects of the anti-cancer drug doxorubicin. Finally,
compound M was injected into both mammary tumor
susceptible MMTV-Neu mice and mouse xenograft models
and was effective in reducing both tumor cell proliferation
and tumor volume [72].
Another large high throughput screen of 65,500 com-
pounds by Rayter et al. [73] identified six compounds that
demonstrated strong inhibition of Wip1 phosphatase activ-
ity. However, only two of these compounds showed growth
inhibitory activity on cancer cell lines. Of these, one
specifically inhibited the growth of cells overexpressing
Wip1, an effect that was lost in the presence of the p38
MAP kinase inhibitor SB203580. This indicated that
suppression of p38 signaling by Wip1 is likely to be an
important component of tumor promotion in some Wip1
overexpressing human cancer cells. The identification of
novel Wip1 small molecule inhibitors is an encouraging
advance and suggests that this approach merits further
consideration for testing in human cancer patients.
8 Other Wip1 biological functions
Aside from its clear importance in DNA damage response
signaling and oncogenesis, the phenotypes observed in
Wip1 knockout mice revealed other key physiological roles
for Wip1. The Wip1 knockout mice display a range of
abnormalities, including variable male runting, male repro-
ductive organ atrophy with reduced male fertility as well as
modestly diminished male longevity [71]. The reproductive
defects of the Wip1−/− mice are only seen in older males
and are presumably related to the abnormal seminiferous
tubules and epididymi with a small number of mature
spermatozoa that arise in these animals. The mechanisms of
runting and reduced longevity seen in the null males may
be a result of hormone level imbalance or deficient steroid
receptor activation. Proia et al. [74] did demonstrate a rather
unexpected regulatory effect of Wip1 on the progesterone
receptor. This study showed that overexpression of Wip1
stimulates steroid receptor activity, by enhancing the
intrinsic activity of p160 coactivators such as steroid
receptor coactivator-1. One result of this activation is that
Wip1 positively regulates the activity of estrogen, proges-
terone, and androgen receptors. This function appears to be
independent of p38 MAPK because SB202190 (a potent
p38MAPK inhibitor) is unable to reverse the inhibition of
the progesterone receptor activity elicited by reducing Wip1
expression in MCF-7 cells.
Mice lacking Wip1 also showed immunological defects.
The Wip1 null mice occasionally exhibited ulcerated skin
lesions, disorganized and hyperplastic lymphoid organs,
and increased inflammation in normal organs. B and T
lymphocytes from Wip1−/− mice displayed a variety of
unbalanced and ineffective responses to antigenic and
mitogenic stimulation [71]. Moreover, Wip1 null mice were
more likely to die from influenza virus infection than their
normal counterparts.
Schito et al. [75] in a more extended analysis of immune
defects in the Wip1 null mice, showed that Wip1 is vital
during the double negative to double positive T cell
transition. Young Wip1 null mice had fewer splenic T cells
and their thymi were smaller with fewer double positive
(DP) and single positive (SP) CD4+ and CD8+ T cells. A
partial block in transition from double negative (DN) to
double positive T cells was noted and this correlates with a
peak in Wip1 mRNA expression in the late DN stages of T
cell maturation. DP T cells that did mature were found to
have cell cycle abnormalities and increased apoptotic rates.
Importantly, when the Wip1 null mice were crossed into a
p53 null strain, many of the thymic and T cell deficiencies
were rescued, indicating that a major component of the
Wip1−/− T cell phenotypes were likely to be due to
increased p53 activity.
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Since the discovery of Wip1 by the Appella laboratory in
1997 there have been many advances in our understanding
of how this p53-induced phosphatase functions. Yet in the
decade or so since its discovery, there have been fewer than
50 papers associated with the study of Wip1, indicating that
we have only scratched the surface in terms of gaining a
complete understanding of the biological role of this
protein. We have learned that Wip1/PPM1D is an oncogene
that functions in part by suppressing major tumor suppres-
sors that include p53. It also plays a homeostatic role in
reversing the effects of the ATM/ATR-initiated DNA
damage response pathway. This homeostatic role is gener-
ally benign until somehow the Wip1 gene becomes
amplified and upregulated. Why and how this abnormal
Wip1 alteration occurs in tumors is unclear, but should be
of much interest in future studies.
Many important questions remain to be answered. The
structure, catalytic activities and functional domains of
Wip1 are still poorly understood. What does the C-terminal
non-catalytic domain do? Are pTXpYand pS/pTQ the only
target motifs recognized by Wip1 or are there others? And
what are the other target proteins? The best guess is that
there are likely to be hundreds of targets, if not more. Does
Wip1 have other undiscovered functions? And perhaps
most importantly, from a disease perspective, how many
human cancers exhibit Wip1 overexpression, what are the
mechanisms for Wip1-mediated oncogenesis, and how can
our knowledge of these mechanisms assist us in designing
novel therapies to fight cancer? The answers to these
questions in the coming years should result in increased
interest in this heretofore little studied protein.
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